Integra LifeSciences Adds to Wound Matrix Line

Integra LifeSciences Corp. has expanded its skin and wound product line with the introduction of Integra Wound Matrix (Thin). Integra Wound Matrix (Thin) recently received 510(k) clearance from the U.S. Food and Drug Administration, and the company expects a full market release in April.

“Integra Wound Matrix (Thin) is a very exciting opportunity for Integra,” said William Weber, vice president and general manager of Integra Extremity Reconstruction. “Our new, thinner product has approximately half the thickness of Integra Wound Matrix and reflects our commitment to offer surgeons enhanced treatment options. The thinner matrix can be applied to complex anatomical sites that require a more conformable graft.”

Integra Wound Matrix (Thin) is a collagen-glycosaminoglycan wound matrix that, according to the company, maintains and supports a healing environment for wound management. It is available in a variety of sizes, it may be used for second degree burns, partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery (microscopically controlled surgery used to treat common types of skin cancer), post-laser surgery, podiatric, wound dehiscence, trauma wounds (abrasions, lacerations, skin tears) and draining wounds. Terminally sterilized, the product is stored at room temperature, has a 24-month shelf life, and is intended for one-time use.

Plainsboro, N.J.-based Integra makes products for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.